Regulation of cysteinyl leukotriene type i receptor
Project Number5R01AI059755-02
Contact PI/Project LeaderPENN, RAYMOND B.
Awardee OrganizationWAKE FOREST UNIVERSITY HEALTH SCIENCES
Description
Abstract Text
DESCRIPTION (provided by applicant): Cysteinyl leukotrienes activate the cysteinyl leukotriene type 1 receptor (CysLT1R) to regulate numerous cell functions important in inflammatory processes and diseases such as asthma. Despite its physiologic importance no studies to date have examined the regulation of CysLT1R signaling or trafficking. We have established model systems for analyzing recombinant human CysLT1R and find regulation of internalization and signaling of the CysLT1R to be unique among GPCRs. Rapid and profound LTD4-stimulated internalization was observed for the wild type (wt) CysLT1R, whereas a C-terminal truncation mutant exhibited impaired internalization yet signaled robustly, and suggested a region within amino acids 309-321 as critical to internalization. Co-expression of arrestin2 or arrestin3 increased agonist-stimulated internalization of wt CysLT1R while inhibiting phosphoinositide (PI) production. However, co-expression of dominant negative arrestins minimally affected internalization, and wt CysLT1R internalized in murine embryonic fibroblasts lacking both arrestin2 and arrestin3, suggesting that arrestins are not the primary physiologic regulators of CysLT1Rs. Instead, pharmacological inhibition of PKC profoundly inhibited CysLT1R internalization while greatly increasing PI production by LTD4, yet had almost no effect on H1 histamine receptor internalization or signaling. Moreover, mutation of putative PKC phosphorylation sites within the CysLT1R C-tail (CysLT1RS(313-316)A) reduced receptor internalization and increased PI production by LTD4, and significantly attenuated the effects of PKC inhibition. Heterologous desensitization by PKC was also observed, as pretreatment with phorbol ester caused a small but significant reduction in PI production with subsequent LTD4 challenge in cells expressing wt CysLT1R but not CysLT1RS(313-316)A. These findings characterize the CysLT1R as the first GPCR identified to date in which PKC is the principal regulator of rapid agonist-dependent internalization and desensitization.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
937727907
UEI
SN7KD2UK7GC5
Project Start Date
15-March-2004
Project End Date
29-February-2008
Budget Start Date
01-March-2005
Budget End Date
28-February-2006
Project Funding Information for 2005
Total Funding
$322,875
Direct Costs
$225,000
Indirect Costs
$97,875
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Allergy and Infectious Diseases
$322,875
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI059755-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI059755-02
Patents
No Patents information available for 5R01AI059755-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI059755-02
Clinical Studies
No Clinical Studies information available for 5R01AI059755-02
News and More
Related News Releases
No news release information available for 5R01AI059755-02
History
No Historical information available for 5R01AI059755-02
Similar Projects
No Similar Projects information available for 5R01AI059755-02